Abstract | IMPORTANCE OF THE FIELD: For patients with advanced non-small cell lung cancer (NSCLC), chemotherapy offers modest benefits and outcomes are poor. Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is a fundamental process for tumor growth and development. Tumor vasculature is therefore emerging as an important target for cancer therapy. AREAS COVERED IN THIS REVIEW: WHAT THE READER WILL GAIN: Expert opinion on the promising results obtained in Phase I studies demonstrating that BIBF 1120 is well tolerated in patients with advanced solid tumors will be provided. Further experience from a Phase II monotherapy trial also indicates promising efficacy and a favorable safety profile in patients with relapsed advanced NSCLC. TAKE HOME MESSAGE: Based on these data, the BIBF 1120 Phase III clinical development program is currently underway and will be discussed in further detail.
|
Authors | Martin Reck |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 19
Issue 6
Pg. 789-94
(Jun 2010)
ISSN: 1744-7658 [Electronic] England |
PMID | 20465363
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Antineoplastic Agents
- Indoles
- nintedanib
|
Topics |
- Angiogenesis Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Animals
- Antineoplastic Agents
(adverse effects, pharmacology, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(blood supply, drug therapy)
- Drug Delivery Systems
- Humans
- Indoles
(adverse effects, pharmacology, therapeutic use)
- Lung Neoplasms
(blood supply, drug therapy)
- Neovascularization, Pathologic
(drug therapy)
|